INCY stock forecast: what analysts expect
Wall Street analysts covering Incyte Corporation currently rate the stock a Buy on average, with a mean 12-month price target of $124.96 — +3.5% versus the last price of $120.77. Targets reflect analyst opinion, not a guarantee.
INCY historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in INCY.
INCY annual returns by year
Congress trading in INCY
3 members of Congress have disclosed trading INCY — 1 purchase and 2 sales worth an estimated $24,000. Most recent disclosure: May 15, 2025.
Insider activity in INCY
INCY's own executives and directors have made 0 open-market purchases ($0) and 21 sales ($14.6M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 5, 2026.
| Aug 5, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Sell | $1.3M |
| Aug 5, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | $273,646 |
| Aug 3, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | $729,204 |
| Jul 31, 2026 | Cagnoni Pablo J | President, Global Head of R&D | Sell | $1.9M |
| Jul 31, 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Sell | $1.8M |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
INCY Key Statistics
INCY in plain English
- P/E ratio (15.4) — how many dollars you pay for each $1 of INCY's yearly profit. That's a fairly normal range.
- ROE (30.67%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (27.71%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend — INCY doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.
INCY stock: frequently asked questions
What is Incyte Corporation's stock price today?
Incyte Corporation (INCY) last traded at $120.77 on the NASDAQ. Over the past 52 weeks the stock has traded between $81.09 and $132.60.
Is INCY stock a buy or a sell?
Wall Street analysts' consensus rating on INCY is "Buy", with an average 12-month price target of $124.96 — about +3.5% versus the current price of $120.77. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in INCY 10 years ago be worth today?
A $1,000 investment in Incyte Corporation made 10 years ago would be worth about $1,489 today (dividends reinvested) — a total return of 49%, or 4.1% per year.
Does INCY pay a dividend?
No — Incyte Corporation does not currently pay a meaningful dividend. Returns for shareholders come from changes in the share price.
What is INCY's P/E ratio?
INCY trades at a trailing price-to-earnings ratio of 15.4, and 13.6 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade INCY stock?
Yes — 3 members of Congress have disclosed trades in INCY under the STOCK Act, totaling 1 purchases and 2 sales worth an estimated $24,000.
What is Incyte Corporation's ticker symbol?
Incyte Corporation trades under the ticker symbol INCY on the NASDAQ.
Compare INCY with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.